Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07632898
PHASE3
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Sponsor: Inhibikase Therapeutics
View on ClinicalTrials.gov
Summary
This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.
Official title: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
484
Start Date
2026-10-23
Completion Date
2030-12-30
Last Updated
2026-06-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
IKT-001
IKT-001 tablets for PO administration